Clinical Trial Update: Study of Efficacy and Safety of Xolair® (Omalizumab) in Chinese Patients With Chronic Spontaneous Urticaria [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating efficacy and safety of Xolair (omalizumab) in Chinese patients with chronic spontaneous urticaria has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spontaneous Urticaria

Drugs mentioned

• Xolair (omalizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Spontaneous Urticaria | Phase 3 | Status: COMPLETED | Results posted: 2020-11-04